Design of Nanoparticle-Based Carriers for Targeted Drug DeliveryXiaojiao Yu, Zi Chen|Journal of Nanomaterials|2016Cited by 261
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapyWei Wang, Shimin Hu, Jörge E. Cortes et al.|Blood|2016Cited by 191
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or AsciminibElias Jabbour, H. Kantarjian, Vivian G. Oehler et al.|JAMA Oncology|2024Cited by 26
First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).Sikander Ailawadhi, Yifan Zhai, Asher Chanan‐Khan et al.|Journal of Clinical Oncology|2021Cited by 25
Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global StudyMatthew S. Davids, Yifan Zhai, Asher Chanan‐Khan et al.|Blood|2022Cited by 16